Treatment Center Outreach Toolkit

Integrating Patient Brochures into Your Website

As a PROVENGE-certified Treatment Center, you can equip your patients with educational brochures to help inform them on everything they need to know about PROVENGE, including important discussion topics to help aid the conversation between your healthcare practitioners and patients. The set of brochures provided below can easily be uploaded on your practice website.

This comprehensive brochure contains key information for patients with advanced prostate cancer who are beginning treatment with PROVENGE, including what it is, how it works, and what to expect during treatment.
Download

This brochure serves as a useful introduction to PROVENGE for patients with advanced prostate cancer considering it as a treatment option, as well as guidance on how to talk to their doctor.
Download

Offer your patients this handy tool that helps them to ask key questions about PROVENGE such as what it is, the benefits it offers, how it works, and what to expect from treatment.
Download



INDICATION: PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION:
Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.

Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please click here for full Prescribing Information.

P-A-01.15-044.00